1. Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib. (22nd July 2021) Authors: Rapposelli, Ilario Giovanni; Tada, Toshifumi; Shimose, Shigeo; Burgio, Valentina; Kumada, Takashi; Iwamoto, Hideki; Hiraoka, Atsushi; Niizeki, Takashi; Atsukawa, Masanori; Koga, Hironori; Hirooka, Masashi; Torimura, Takuji; Iavarone, Massimo; Tortora, Raffaella; Campani, Claudia; Lonardi, Sara; T... Journal: Liver international Issue: Volume 41:Number 12(2021) Page Start: 2997 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab. (14th December 2022) Authors: Tada, Toshifumi; Kumada, Takashi; Hiraoka, Atsushi; Hirooka, Masashi; Kariyama, Kazuya; Tani, Joji; Atsukawa, Masanori; Takaguchi, Koichi; Itobayashi, Ei; Fukunishi, Shinya; Tsuji, Kunihiko; Ishikawa, Toru; Tajiri, Kazuto; Ochi, Hironori; Yasuda, Satoshi; Toyoda, Hidenori; Ogawa, Chikara; Nishimu... Journal: Cancer medicine Issue: Volume 12:Number 7(2023) Page Start: 7772 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Analysis of efficacy of lenvatinib treatment in highly advanced hepatocellular carcinoma with tumor thrombus in the main trunk of the portal vein or tumor with more than 50% liver occupation: A multicenter analysis. Issue 2 (5th January 2021) Authors: Chuma, Makoto; Uojima, Haruki; Hiraoka, Atsushi; Kobayashi, Satoshi; Toyoda, Hidenori; Tada, Toshifumi; Hidaka, Hisashi; Iwabuchi, Shogo; Numata, Kazushi; Itobayashi, Ei; Itokawa, Norio; Kariyama, Kazuya; Ohama, Hideko; Hattori, Nobuhiro; Hirose, Shunji; Shibata, Hiroshi; Tani, Joji; Imai, Michit... Journal: Hepatology research Issue: Volume 51:Issue 2(2021) Page Start: 201 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysis. Issue 5 (9th February 2022) Authors: Hatanaka, Takeshi; Hiraoka, Atsushi; Tada, Toshifumi; Hirooka, Masashi; Kariyama, Kazuya; Tani, Joji; Atsukawa, Masanori; Takaguchi, Koichi; Itobayashi, Ei; Fukunishi, Shinya; Tsuji, Kunihiko; Ishikawa, Toru; Tajiri, Kazuto; Ochi, Hironori; Yasuda, Satoshi; Toyoda, Hidenori; Ogawa, Chikara; Nishi... Journal: Hepatology research Issue: Volume 52:Issue 5(2022) Page Start: 462 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience. Issue 2 (11th June 2021) Authors: Hiraoka, Atsushi; Kumada, Takashi; Tada, Toshifumi; Hirooka, Masashi; Kariyama, Kazuya; Tani, Joji; Atsukawa, Masanori; Takaguchi, Koichi; Itobayashi, Ei; Fukunishi, Shinya; Tsuji, Kunihiko; Ishikawa, Toru; Tajiri, Kazuto; Ochi, Hironori; Yasuda, Satoshi; Toyoda, Hidenori; Ogawa, Chikara; Nishimu... Journal: Cancer reports Issue: Volume 5:Issue 2(2022) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population. (February 2023) Authors: Casadei-Gardini, Andrea; Rimini, Margherita; Tada, Toshifumi; Suda, Goki; Shimose, Shigeo; Kudo, Masatoshi; Cheon, Jaekyung; Finkelmeier, Fabian; Lim, Ho Yeong; Rimassa, Lorenza; Presa, José; Masi, Gianluca; Yoo, Changhoon; Lonardi, Sara; Tovoli, Francesco; Kumada, Takashi; Sakamoto, Naoya; Iwamo... Journal: European journal of cancer Issue: Volume 180(2023) Page Start: 9 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Clinical features of patients with chronic liver disease in Japan related to alcohol use: Nationwide examination using alcohol use disorders identification test. Issue 1 (15th September 2022) Authors: Hiraoka, Atsushi; Nakai, Masato; Hara, Nagisa; Hanai, Tatsunori; Namisaki, Tadashi; Miyaaki, Hisamitsu; Nakahara, Takashi; Hiramatsu, Akira; Ohama, Hideko; Tada, Fujimasa; Takahashi, Hirokazu; Aikata, Hiroshi; Eguchi, Yuichiro; Hiasa, Yoichi; Yoshiji, Hitoshi Journal: Hepatology research Issue: Volume 53:Issue 1(2023) Page Start: 43 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weighting. Issue 7 (29th November 2020) Authors: Hiraoka, Atsushi; Kumada, Takashi; Kariyama, Kazuya; Tada, Toshifumi; Tani, Joji; Fukunishi, Shinya; Atsukawa, Masanori; Hirooka, Masashi; Tsuji, Kunihiko; Ishikawa, Toru; Takaguchi, Koichi; Itobayashi, Ei; Tajiri, Kazuto; Shimada, Noritomo; Shibata, Hiroshi; Ochi, Hironori; Kawata, Kazuhito; Yas... Journal: Journal of gastroenterology and hepatology Issue: Volume 36:Issue 7(2021) Page Start: 1812 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Does first‐line treatment have prognostic impact for unresectable HCC?—Atezolizumab plus bevacizumab versus lenvatinib. (3rd June 2022) Authors: Hiraoka, Atsushi; Kumada, Takashi; Tada, Toshifumi; Hirooka, Masashi; Kariyama, Kazuya; Tani, Joji; Atsukawa, Masanori; Takaguchi, Koichi; Itobayashi, Ei; Fukunishi, Shinya; Tsuji, Kunihiko; Ishikawa, Toru; Tajiri, Kazuto; Ochi, Hironori; Yasuda, Satoshi; Toyoda, Hidenori; Ogawa, Chikara; Nishimu... Journal: Cancer medicine Issue: Volume 12:Number 1(2023) Page Start: 325 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC‐B stage patients classified as beyond up to seven criteria – Multicenter analysis. Issue 3 (2nd December 2021) Authors: Hiraoka, Atsushi; Kumada, Takashi; Tada, Toshifumi; Hirooka, Masashi; Kariyama, Kazuya; Tani, Joji; Atsukawa, Masanori; Takaguchi, Koichi; Itobayashi, Ei; Fukunishi, Shinya; Tsuji, Kunihiko; Ishikawa, Toru; Tajiri, Kazuto; Ochi, Hironori; Yasuda, Satoshi; Toyoda, Hidenori; Ogawa, Chikara; Nishimu... Journal: Hepatology research Issue: Volume 52:Issue 3(2022) Page Start: 308 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗